Celon Pharma Past Earnings Performance
Past criteria checks 2/6
Celon Pharma's earnings have been declining at an average annual rate of -45.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 12.3% per year. Celon Pharma's return on equity is 3.6%, and it has net margins of 8.8%.
Key information
-45.3%
Earnings growth rate
-45.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 29.4% |
| Revenue growth rate | 12.3% |
| Return on equity | 3.6% |
| Net Margin | 8.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Statutory Earnings May Not Be The Best Way To Understand Celon Pharma's (WSE:CLN) True Position
Nov 28
A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price
Aug 21Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates
Sep 24Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans
Jul 13We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow
Nov 04We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth
Aug 04Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly
May 23Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)
Mar 02Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Feb 09
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?
Jan 20Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain
Dec 24Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet
Dec 03Revenue & Expenses Breakdown
How Celon Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 210 | 19 | 121 | 0 |
| 30 Jun 24 | 207 | -45 | 119 | 0 |
| 31 Mar 24 | 209 | -34 | 112 | 0 |
| 31 Dec 23 | 214 | -28 | 111 | 0 |
| 30 Sep 23 | 214 | -25 | 108 | 0 |
| 30 Jun 23 | 211 | -30 | 108 | 0 |
| 31 Mar 23 | 196 | -47 | 111 | 0 |
| 31 Dec 22 | 194 | -39 | 108 | 0 |
| 30 Sep 22 | 191 | -31 | 108 | 0 |
| 30 Jun 22 | 186 | -28 | 100 | 0 |
| 31 Mar 22 | 191 | -17 | 96 | 0 |
| 31 Dec 21 | 196 | -12 | 90 | 0 |
| 30 Sep 21 | 186 | -11 | 89 | 0 |
| 30 Jun 21 | 185 | -2 | 86 | 0 |
| 31 Mar 21 | 170 | 0 | 91 | -10 |
| 31 Dec 20 | 157 | -1 | 83 | 0 |
| 30 Sep 20 | 142 | 4 | 72 | 0 |
| 30 Jun 20 | 128 | 5 | 70 | 0 |
| 31 Mar 20 | 109 | 3 | 63 | 10 |
| 31 Dec 19 | 102 | 12 | 62 | 0 |
| 30 Sep 19 | 110 | 17 | 60 | 0 |
| 30 Jun 19 | 118 | 23 | 38 | 0 |
| 31 Mar 19 | 124 | 29 | 40 | 0 |
| 31 Dec 18 | 125 | 30 | 37 | 0 |
| 30 Sep 18 | 116 | 30 | 33 | 0 |
| 30 Jun 18 | 109 | 26 | 47 | 0 |
| 31 Mar 18 | 107 | 28 | 35 | 0 |
| 31 Dec 17 | 107 | 26 | 35 | 0 |
| 30 Sep 17 | 129 | 22 | 41 | 0 |
| 30 Jun 17 | 127 | 24 | 41 | 0 |
| 31 Mar 17 | 115 | 27 | 31 | 0 |
| 31 Dec 16 | 129 | 38 | 34 | 0 |
| 30 Sep 16 | 111 | 42 | 55 | 0 |
| 31 Dec 15 | 108 | 37 | 55 | 0 |
| 31 Dec 14 | 98 | 52 | 51 | 0 |
Quality Earnings: CLN has high quality earnings.
Growing Profit Margin: CLN became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLN's earnings have declined by 45.3% per year over the past 5 years.
Accelerating Growth: CLN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CLN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).
Return on Equity
High ROE: CLN's Return on Equity (3.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 09:05 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Celon Pharma S.A. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Vladimira Urbankova | Erste Group Bank AG |